Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine · 27.07.2023 · 389 (4) · 335-347
DOI: 10.1056/nejmoa2303379 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 27.07.2023. Verfasst von Jesús San-Miguel und 42 weiteren Autor:innen. Beteiligte Einrichtung: From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigac…. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Immunotherapy, Adoptive, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 852-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Janssen Research & Development, LLC, Legend Biotech USA Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the Univer…
ORCID-Profile: Binod Dhakal, Luciano J Costa
Förderung
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
Zitieren
APA
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., …, & Einsele, H. (2023). Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine, 389(4), 335-347. https://doi.org/10.1056/nejmoa2303379
Vancouver
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine. 2023;389(4):335-347. doi:10.1056/nejmoa2303379
BibTeX
@article{SanMiguel2023,
author = {San-Miguel, Jesús and Dhakal, Binod and Yong, Kwee and Spencer, Andrew and Anguille, Sébastien and Mateos, María-Victoria and Fernández de Larrea, Carlos and Martínez-López, Joaquín and Moreau, Philippe and Touzeau, Cyrille and Leleu, Xavier and Avivi, Irit and Cavo, Michele and Ishida, Tadao and Kim, Seok Jin and Roeloffzen, Wilfried and van de Donk, Niels W C J and Dytfeld, Dominik and Sidana, Surbhi and Costa, Luciano J and Oriol, Albert and Popat, Rakesh and Khan, Abdullah M and Cohen, Yaël C and Ho, P Joy and Griffin, James and Lendvai, Nikoletta and Lonardi, Carolina and Slaughter, Ana and Schecter, Jordan M and Jackson, Carolyn C and Connors, Kaitlyn and Li, Katherine and Zudaire, Enrique and Chen, Diana and Gilbert, Jane and Yeh, Tzu-Min and Nagle, Sarah and Florendo, Erika and Pacaud, Lida and Patel, Nitin and Harrison, Simon J and Einsele, Hermann},
title = {Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {4},
pages = {335--347},
doi = {10.1056/nejmoa2303379}
}
EUVIMED